<p>Palvella Therapeutics, Inc.（纳斯达克代码：PVLA - 获取免费报告）的股票在周二上涨了 6.6%，因为 Canaccord Genuity Group 将该股票的目标价从 148.00 美元上调至 204.00 美元。Canaccord Genuity Group 目前对该股票给予买入评级。Palvella Therapeutics 的股价最高达到 95.08 美元，最后交易价为 94.81 美元。在午盘交易中，共成交 136,382 股，较平均交易量 131,872 股增加了 3%。该股票此前收盘价为 88.98 美元。</p>
<p>获取 <strong>Palvella Therapeutics</strong> 的提醒：</p>
<p>其他分析师也对该股票发布了研究报告。BTIG Research 在周一将 Palvella Therapeutics 的目标价从 167.00 美元上调至 192.00 美元，并给予该股票 “买入” 评级。HC Wainwright 在周一的研究报告中设定了 Palvella Therapeutics 的目标价为 200.00 美元。Truist Financial 在周一将 Palvella Therapeutics 的目标价从 105.00 美元上调至 190.00 美元，并给予该公司 “买入” 评级。Oppenheimer 在周一重申了 “跑赢大盘” 的评级，并设定了 Palvella Therapeutics 的目标价为 200.00 美元。最后，Chardan Capital 在周一将 Palvella Therapeutics 的目标价从 110.00 美元上调至 174.00 美元，并给予该股票 “买入” 评级。两位分析师给予该股票强烈买入评级，十四位分析师给予买入评级，一位分析师给予卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “买入”，共识目标价为 155.60 美元。</p>
<p><strong>查看我们最新的 PVLA 股票分析</strong></p>
<h2>内部活动</h2>
<p>在其他新闻中，首席运营官 Kathleen Goin 于 11 月 19 日星期三出售了 4,302 股公司的股票。股票以 86.23 美元的平均价格出售，总价值为 370,961.46 美元。该交易在向 SEC 提交的文件中披露，文件可通过此链接访问。20.50% 的股票由公司内部人士持有。</p>
<h2>机构投资者对 Palvella Therapeutics 的看法</h2>
<p>几家机构投资者和对冲基金最近增加或减少了对该公司的持股。Archer Investment Corp 在第三季度购买了 Palvella Therapeutics 的新头寸，价值约 28,000 美元。Russell Investments Group Ltd.在第三季度购买了 Palvella Therapeutics 的新头寸，价值约 36,000 美元。新泽西州警察和消防员退休系统在第二季度获得了 Palvella Therapeutics 的新头寸，价值约 37,000 美元。AlphaQuest LLC 在第三季度获得了 Palvella Therapeutics 的新头寸，价值约 164,000 美元。最后，摩根大通在第二季度将其在 Palvella Therapeutics 的持股增加了 108,066.7%。摩根大通现在拥有 3,245 股该公司的股票，价值 73,000 美元，此前在上个季度又购买了 3,242 股。40.11% 的股票由机构投资者持有。</p>
<h2>Palvella Therapeutics 股票表现</h2>
<p>该公司的 50 日移动平均价格为 83.82 美元，200 日移动平均价格为 55.62 美元。该公司的市值为 11.2 亿美元，市盈率为-36.10，贝塔值为-0.20。</p>
<p>Palvella Therapeutics（纳斯达克代码：PVLA - 获取免费报告）最近于 11 月 10 日星期一发布了季度财报。该公司报告每股收益（EPS）为-1.03 美元，低于市场共识预期的-0.85 美元，差距为 0.18 美元。分析师平均预计 Palvella Therapeutics, Inc.在当前财年将发布-3.69 美元的每股收益。</p>
<h2>Palvella Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Palvella Therapeutics Inc 是一家临床阶段的生物制药公司，专注于开发和商业化新型疗法，以治疗患有严重、罕见遗传皮肤病的患者。Palvella Therapeutics Inc，前身为 Pieris Pharmaceuticals Inc，总部位于宾夕法尼亚州韦恩。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Palvella Therapeutics</li>
<li>如何投资保险公司：指南</li>
<li>三只大规模回购的 AI 股票：GEV、PSTG 和 LSCC 信号信心</li>
<li>投资者需要了解即将上市的 IPO</li>
<li>西部数据的纳斯达克 100 入选标志着其 AI 驱动的复苏</li>
<li>三只值得长期持有的 REITs</li>
<li>派拉蒙在 Netflix 收购华纳兄弟的竞标中扔了一颗扳手。</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Palvella Therapeutics 吗？</h2>
<p>在考虑 Palvella Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Palvella Therapeutics 并不在名单上。</p>
<p>虽然 Palvella Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PVLA

<p>Palvella Therapeutics（纳斯达克代码：PVLA）股价上涨 6.6%，因 Canaccord Genuity Group 将其目标价从 148 美元上调至 204 美元，并维持买入评级。其他分析师也提高了他们的目标价，进一步推动了股价的上涨。机构投资者已调整其持股比例，40.11% 的股份由他们持有。该公司报告的季度每股收益为（1.03 美元），未达到预期。Palvella Therapeutics 专注于罕见遗传性皮肤疾病的治疗</p>

<p>Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) shot up 6.6% on Tuesday after Canaccord Genuity Group raised their price target on the stock from $148.00 to $204.00. Canaccord Genuity Group currently has a buy rating on the stock. Palvella Therapeutics traded as high as $95.08 and last traded at $94.81. 136,382 shares were traded during mid-day trading, an increase of 3% from the average session volume of 131,872 shares. The stock had previously closed at $88.98.</p>
<div class="lb-trans"><p>Palvella Therapeutics, Inc.（纳斯达克代码：PVLA - 获取免费报告）的股票在周二上涨了 6.6%，因为 Canaccord Genuity Group 将该股票的目标价从 148.00 美元上调至 204.00 美元。Canaccord Genuity Group 目前对该股票给予买入评级。Palvella Therapeutics 的股价最高达到 95.08 美元，最后交易价为 94.81 美元。在午盘交易中，共成交 136,382 股，较平均交易量 131,872 股增加了 3%。该股票此前收盘价为 88.98 美元。</p>
</div><p>Get <strong>Palvella Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Palvella Therapeutics</strong> 的提醒：</p>
</div><p>Other analysts have also issued research reports about the stock. BTIG Research lifted their target price on shares of Palvella Therapeutics from $167.00 to $192.00 and gave the stock a &#34;buy&#34; rating in a report on Monday. HC Wainwright set a $200.00 price objective on Palvella Therapeutics in a research note on Monday. Truist Financial upped their price objective on Palvella Therapeutics from $105.00 to $190.00 and gave the company a &#34;buy&#34; rating in a report on Monday. Oppenheimer restated an &#34;outperform&#34; rating and set a $200.00 target price on shares of Palvella Therapeutics in a report on Monday. Finally, Chardan Capital boosted their target price on Palvella Therapeutics from $110.00 to $174.00 and gave the stock a &#34;buy&#34; rating in a research report on Monday. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of &#34;Buy&#34; and a consensus target price of $155.60.</p>
<div class="lb-trans"><p>其他分析师也对该股票发布了研究报告。BTIG Research 在周一将 Palvella Therapeutics 的目标价从 167.00 美元上调至 192.00 美元，并给予该股票 “买入” 评级。HC Wainwright 在周一的研究报告中设定了 Palvella Therapeutics 的目标价为 200.00 美元。Truist Financial 在周一将 Palvella Therapeutics 的目标价从 105.00 美元上调至 190.00 美元，并给予该公司 “买入” 评级。Oppenheimer 在周一重申了 “跑赢大盘” 的评级，并设定了 Palvella Therapeutics 的目标价为 200.00 美元。最后，Chardan Capital 在周一将 Palvella Therapeutics 的目标价从 110.00 美元上调至 174.00 美元，并给予该股票 “买入” 评级。两位分析师给予该股票强烈买入评级，十四位分析师给予买入评级，一位分析师给予卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “买入”，共识目标价为 155.60 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on PVLA</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 PVLA 股票分析</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other news, COO Kathleen Goin sold 4,302 shares of the business's stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $86.23, for a total value of $370,961.46. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 20.50% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他新闻中，首席运营官 Kathleen Goin 于 11 月 19 日星期三出售了 4,302 股公司的股票。股票以 86.23 美元的平均价格出售，总价值为 370,961.46 美元。该交易在向 SEC 提交的文件中披露，文件可通过此链接访问。20.50% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Palvella Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Palvella Therapeutics 的看法</h2>
</div><p>Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Archer Investment Corp bought a new position in shares of Palvella Therapeutics in the 3rd quarter valued at about $28,000. Russell Investments Group Ltd. bought a new position in Palvella Therapeutics in the third quarter valued at approximately $36,000. Police &amp; Firemen s Retirement System of New Jersey acquired a new position in shares of Palvella Therapeutics during the 2nd quarter worth approximately $37,000. AlphaQuest LLC acquired a new position in shares of Palvella Therapeutics during the 3rd quarter worth approximately $164,000. Finally, JPMorgan Chase &amp; Co. raised its stake in shares of Palvella Therapeutics by 108,066.7% during the 2nd quarter. JPMorgan Chase &amp; Co. now owns 3,245 shares of the company's stock worth $73,000 after purchasing an additional 3,242 shares in the last quarter. 40.11% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近增加或减少了对该公司的持股。Archer Investment Corp 在第三季度购买了 Palvella Therapeutics 的新头寸，价值约 28,000 美元。Russell Investments Group Ltd.在第三季度购买了 Palvella Therapeutics 的新头寸，价值约 36,000 美元。新泽西州警察和消防员退休系统在第二季度获得了 Palvella Therapeutics 的新头寸，价值约 37,000 美元。AlphaQuest LLC 在第三季度获得了 Palvella Therapeutics 的新头寸，价值约 164,000 美元。最后，摩根大通在第二季度将其在 Palvella Therapeutics 的持股增加了 108,066.7%。摩根大通现在拥有 3,245 股该公司的股票，价值 73,000 美元，此前在上个季度又购买了 3,242 股。40.11% 的股票由机构投资者持有。</p>
</div><h2>Palvella Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Palvella Therapeutics 股票表现</h2>
</div><p>The firm has a fifty day moving average price of $83.82 and a 200 day moving average price of $55.62. The company has a market cap of $1.12 billion, a price-to-earnings ratio of -36.10 and a beta of -0.20.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均价格为 83.82 美元，200 日移动平均价格为 55.62 美元。该公司的市值为 11.2 亿美元，市盈率为-36.10，贝塔值为-0.20。</p>
</div><p>Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.18). On average, analysts expect that Palvella Therapeutics, Inc. will post -3.69 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Palvella Therapeutics（纳斯达克代码：PVLA - 获取免费报告）最近于 11 月 10 日星期一发布了季度财报。该公司报告每股收益（EPS）为-1.03 美元，低于市场共识预期的-0.85 美元，差距为 0.18 美元。分析师平均预计 Palvella Therapeutics, Inc.在当前财年将发布-3.69 美元的每股收益。</p>
</div><h2>Palvella Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Palvella Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.</p>
<div class="lb-trans"><p>Palvella Therapeutics Inc 是一家临床阶段的生物制药公司，专注于开发和商业化新型疗法，以治疗患有严重、罕见遗传皮肤病的患者。Palvella Therapeutics Inc，前身为 Pieris Pharmaceuticals Inc，总部位于宾夕法尼亚州韦恩。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Palvella Therapeutics</li>
<li>How to Invest in Insurance Companies: A Guide</li>
<li>3 AI Names With Big Buybacks: GEV, PSTG, and LSCC Signal Confidence</li>
<li>What Investors Need to Know About Upcoming IPOs</li>
<li>Western Digital’s Nasdaq-100 Entry Caps Its AI-Driven Comeback</li>
<li>3 REITs to Buy and Hold for the Long Term</li>
<li>Paramount Threw a Wrench in Netflix's Bid to Acquire Warner Bros.</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Palvella Therapeutics</li>
<li>如何投资保险公司：指南</li>
<li>三只大规模回购的 AI 股票：GEV、PSTG 和 LSCC 信号信心</li>
<li>投资者需要了解即将上市的 IPO</li>
<li>西部数据的纳斯达克 100 入选标志着其 AI 驱动的复苏</li>
<li>三只值得长期持有的 REITs</li>
<li>派拉蒙在 Netflix 收购华纳兄弟的竞标中扔了一颗扳手。</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Palvella Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Palvella Therapeutics 吗？</h2>
</div><p>Before you consider Palvella Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Palvella Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palvella Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Palvella Therapeutics 并不在名单上。</p>
</div><p>While Palvella Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Palvella Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Palvella Therapeutics（纳斯达克股票代码：PVLA）因分析师上调评级而股价上涨 6.6%